Page last updated: 2024-11-11

mitemcinal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mitemcinal: a motilin agonist on rabbit duodenum [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918267
CHEMBL ID2110756
SCHEMBL ID13524619
MeSH IDM0515695

Synonyms (17)

Synonym
154738-42-8
6x5nrj664l ,
unii-6x5nrj664l
mitemcinal [inn]
(2s,4r,5r,8r,9s,10s,11r,12r)-5-ethyl-9-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3r,4s,6r)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-
de(n-methyl)-11-deoxy-n-isopropyl-12-o-methyl-11-oxo-8,9-anhydroerythromycin a 6,9-hemiacetal fumaric acid
mitemcinal
bdbm85390
mitemcinal [who-dd]
8,9-didehydro-n-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-n-isopropyl-12-o-methyl-11-oxoerythromycin
erythromycin, 8,9-didehydro-n-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-12-o-methyl n-(1-methylethyl)-11-oxo-
SCHEMBL13524619
CHEMBL2110756
DB06587
8,9-didehydro-n-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-12-o-methyl-n-(1-methylethyl)-11-oxoerythromycin
Q14200353
DTXSID00870028

Research Excerpts

Overview

Mitemcinal (GM-611) is a macrolide motilin receptor agonist with acid-resistance and without antibiotic activity. M itemcinal fumarate is an erythromycin derivative with two pseudo-polymorphic forms, hydrate and anhydrate.

ExcerptReferenceRelevance
"Mitemcinal is an erythromycin derivative with motilin agonistic action, developed as a gastrointestinal motor-activating agent. "( Characterization of multinuclear hepatocytes induced in rats by mitemcinal (GM-611), an erythromycin derivative.
Fujii, E; Hayashi, S; Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Sugimoto, T; Suzuki, M; Takanashi, H; Wanibuchi, H, 2008
)
2.03
"Mitemcinal fumarate is an erythromycin derivative with two pseudo-polymorphic forms, hydrate and anhydrate."( Characterization and monitoring of pseudo-polymorphs in manufacturing process by NIR.
Kamada, K; Murata, H; Murata, M; Nagai, H; Terada, K; Ushio, H; Yoshimura, S, 2009
)
1.07
"Mitemcinal (GM-611) is a macrolide motilin receptor agonist with acid-resistance and without antibiotic activity. "( Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis.
Cynshi, O; Takanashi, H, 2009
)
2.05
"Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor. "( Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Itoh, M; Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Tabo, M; Takanashi, H, 2007
)
2.05
"Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor. "( Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model.
Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Tabo, M; Takanashi, H, 2007
)
2.04
"Mitemcinal is an orally active motilin agonist that could potentially improve gastric emptying."( Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study.
Cynshi, O; McCallum, RW, 2007
)
2.08
"Mitemcinal is an erythromycin derivative, which acts as an agonist of the motilin receptor. "( Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study.
Fujii, E; Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Takanashi, H, 2008
)
2.05

Actions

ExcerptReferenceRelevance
"Mitemcinal caused an increase in the GMC-index (integration of contractile amplitude and duration) and proximal translocation of the GMC starting point, but did not cause an increase in the number of defecations 12 h after administration."( Stimulatory action of mitemcinal (GM-611), an acid-resistant non-peptide motilin receptor agonist, on colonic motor activity and defecation: spontaneous and mitemcinal-induced giant migrating contractions during defecation in dogs.
Hagane, K; Hirabayashi, T; Hoshino, K; Matsufuji, H; Morikawa, Y; Ozaki, K, 2009
)
1.39

Dosage Studied

ExcerptRelevanceReference
"In a randomized, double-blind design, 106 patients were randomized into four dosing regimens (22 to placebo and 21 each to mitemcinal 10 mg, 20 mg, 30 mg bid or 20 mg tid) for 28 days."( Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study.
Cynshi, O; McCallum, RW, 2007
)
0.85
" Cisapride (1, 3 and 10 mg/kg) caused non-significant increases in the indices of gastric emptying, with roughly bell-shaped dose-response curves."( Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs.
Akima, M; Itoh, Z; Kamei, K; Koga, H; Omura, S; Onoma, M; Ozaki, K; Takanashi, H; Yogo, K, 2008
)
0.86
" They also indicate that the increased incidence of lymphomas was based on a non-genotoxic effect with a threshold dose-response and that the tumorigenesis was based on the strain or species specificity of background factors."( Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study.
Fujii, E; Itoh, Z; Kato, A; Kimura, K; Mizoguchi, K; Omura, S; Suzuki, M; Takanashi, H, 2008
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (13.04)18.2507
2000's20 (86.96)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.33 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews3 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]